Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial
Clinical Endocrinology · 2024
DOI: 10.1111/cen.15025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Jun Mori und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism, Pituitary, Histidine, Mannitol. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
Somapacitan is a long‐acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily GH.
Design
Subanalysis on Japanese patients from a randomised, open‐labelled, controlled parallel‐group phase 3 trial (REAL4, NCT03811535). Patients and Measurements Thirty treatment‐naïve patients were randomised 2:1 to somapacitan (0.16 mg/kg/week) or daily GH (0.034 mg/kg/day) up to Week 52, after which all patients received somapacitan. Height velocity (HV; cm/year) at Weeks 52 and 104 were the primary measurements. Additional assessments included HV SD score (SDS), height SDS, bone age, insulin‐like growth factor‐I (IGF‐I) SDS, and observer‐reported outcomes.
Results
At Week 52, observed mean HV was similar between treatment groups (10.3 vs. 9.8 cm/year for somapacitan and daily GH, respectively). Similar HVs between groups were also observed at Week 104: 7.4 cm/year after continuous somapacitan treatment (soma/soma) and 7.9 cm/year after 1‐year somapacitan treatment following switch from daily GH (switch). Other height‐related endpoints supported continuous growth. IGF‐I SDS increased in both groups with mean IGF‐I SDS within −2 and +2 during the study. Somapacitan was well tolerated, one mild injection site reaction was reported, with no reports of injection site pain. Patient preference questionnaires showed that most patients and their caregivers (90.9%) who switched treatment at Week 52 preferred once‐weekly somapacitan over daily GH treatment.
Conclusions
Somapacitan showed sustained efficacy in Japanese children with GHD over 104 weeks and for 52 weeks after switching from daily GH. Somapacitan was well tolerated and preferred over daily GH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
- Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Rare Disease Group, Novo Nordisk Pharma Ltd., Tokyo, Japan.
- Global Medical Affairs, Novo Nordisk Health Care AG, Zürich, Switzerland.
- Medical and Science, Rare Disease and Advanced Therapies, Clinical Drug Development, Novo Nordisk A/S, Søborg, Denmark.
ORCID-Profile: Michael Højby Rasmussen
Förderung
- Novo Nordisk
Zitieren
APA
Mori, J., Ohata, Y., Fujisawa, Y., Sato, Y., Röhrich, S., Rasmussen, M. H., Bang, R. B., & Horikawa, R. (2024). Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical Endocrinology. https://doi.org/10.1111/cen.15025
Vancouver
Mori J, Ohata Y, Fujisawa Y, Sato Y, Röhrich S, Rasmussen MH, et al. Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clinical Endocrinology. 2024. doi:10.1111/cen.15025
BibTeX
@article{Mori2024,
author = {Mori, Jun and Ohata, Yasuhisa and Fujisawa, Yasuko and Sato, Yukihito and Röhrich, Sebastian and Rasmussen, Michael Højby and Bang, Rikke Beck and Horikawa, Reiko},
title = {Effective growth hormone replacement with once‐weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.15025}
}
EUVIMED